Market Closed -
Nasdaq
16:00:00 2024-05-08 EDT
|
5-day change
|
1st Jan Change
|
6.4
USD
|
-5.88%
|
|
-14.55%
|
-3.03%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,004
|
505.8
|
292.4
|
323.9
|
479.2
|
-
|
-
|
Enterprise Value (EV)
1 |
2,004
|
505.8
|
292.4
|
323.9
|
479.2
|
479.2
|
479.2
|
P/E ratio
|
-11.3
x
|
-5.86
x
|
-2.3
x
|
-2.75
x
|
-3.04
x
|
-2.9
x
|
-2.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
44.9
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
44.9
x
|
EV / EBITDA
|
-
|
-5.97
x
|
-2.51
x
|
-2.57
x
|
-4.2
x
|
-4.13
x
|
-3.82
x
|
EV / FCF
|
-39.3
x
|
-6.93
x
|
-2.81
x
|
-2.83
x
|
-4.32
x
|
-3.77
x
|
-2.87
x
|
FCF Yield
|
-2.55%
|
-14.4%
|
-35.6%
|
-35.3%
|
-23.2%
|
-26.5%
|
-34.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32,595
|
32,949
|
48,814
|
49,072
|
70,468
|
-
|
-
|
Reference price
2 |
61.47
|
15.35
|
5.990
|
6.600
|
6.400
|
6.400
|
6.400
|
Announcement Date
|
21-03-25
|
22-03-17
|
23-03-16
|
24-03-21
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
10.68
|
EBITDA
1 |
-
|
-
|
-84.67
|
-116.3
|
-125.8
|
-114
|
-116
|
-125.3
|
EBIT
1 |
-
|
-51.51
|
-86.43
|
-119
|
-131.6
|
-119.7
|
-135.3
|
-161.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,512.55%
|
Earnings before Tax (EBT)
1 |
-
|
-91.36
|
-86.08
|
-113.8
|
-117.5
|
-107.7
|
-126.4
|
-151.1
|
Net income
1 |
-21.08
|
-91.36
|
-86.08
|
-113.8
|
-117.5
|
-107.7
|
-131.4
|
-150.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,410.48%
|
EPS
2 |
-3.890
|
-5.440
|
-2.620
|
-2.610
|
-2.400
|
-2.103
|
-2.208
|
-2.340
|
Free Cash Flow
1 |
-
|
-51.02
|
-72.95
|
-104.1
|
-114.3
|
-111
|
-127
|
-167
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,563.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-06-19
|
21-03-25
|
22-03-17
|
23-03-16
|
24-03-21
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-25.49
|
-26.98
|
-29.6
|
-34.25
|
-33.52
|
-36.02
|
-27.31
|
-28.93
|
-29
|
-28
|
-28
|
-28
|
-29
|
EBIT
1 |
-22.43
|
-22.89
|
-26.1
|
-27.61
|
-30.26
|
-34.98
|
-34.31
|
-36.86
|
-29.29
|
-31.18
|
-29.18
|
-29.17
|
-29.78
|
-31.55
|
-30.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.35
|
-22.81
|
-25.99
|
-26.92
|
-28.34
|
-32.58
|
-30.82
|
-33.29
|
-25.64
|
-27.75
|
-26.31
|
-26.01
|
-26.72
|
-28.65
|
-29.85
|
Net income
1 |
-22.35
|
-22.81
|
-25.99
|
-26.92
|
-28.34
|
-32.58
|
-30.82
|
-33.29
|
-25.64
|
-27.75
|
-26.31
|
-26.11
|
-26.72
|
-28.65
|
-29.85
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6800
|
-0.6900
|
-0.7900
|
-0.6100
|
-0.5800
|
-0.6700
|
-0.6300
|
-0.6800
|
-0.5200
|
-0.5700
|
-0.5586
|
-0.5200
|
-0.5229
|
-0.5157
|
-0.5533
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-10
|
22-03-17
|
22-05-12
|
22-08-11
|
22-11-09
|
23-03-16
|
23-05-11
|
23-08-10
|
23-11-09
|
24-03-21
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-51
|
-73
|
-104
|
-114
|
-111
|
-127
|
-167
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
7.51
|
5.03
|
47.1
|
28.1
|
12
|
14
|
17
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
159.12%
|
Announcement Date
|
20-06-19
|
21-03-25
|
22-03-17
|
23-03-16
|
24-03-21
|
-
|
-
|
-
|
Average target price
19.25
USD Spread / Average Target +200.78% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.03% | 479M | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|